Frank Mottola - 06 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: SVP, Chief Tech. Ops. Officer
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 06 Mar 2026
Net transactions value: -$87,074
Form type: 4
Filing time: 10 Mar 2026, 16:13:22 UTC
Previous filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Mottola Frank	SVP, Chief Tech. Ops. Officer	C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE	/s/ Timothy C. Dec, as attorney-in-fact	10 Mar 2026	0001804567

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise		+3,750	+21%	$0.000000^*	21,856	06 Mar 2026	Direct
transaction	SUPN	Common Stock	Tax liability		-1,793	-8.2%	$54.73^*	20,063	06 Mar 2026	Direct	F1
transaction	SUPN	Common Stock	Sale	$87,074	-1,623	-8.1%	$53.65	18,440	09 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise		-3,750	-100%	$0.000000^*	0	06 Mar 2026	Common Stock	3,750	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2	On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.